Vedolizumab (Entyvio) for Crohn's Disease: A Patient Guide

If you have been told that vedolizumab for Crohn's disease might be the next step in your treatment, you are probably full of questions - and maybe a little nervous about what this biologic actually does inside your body. Many of us in the Crohn's community have been in that exact moment, weighing the hope of a new therapy against the uncertainty that comes with it. This guide walks through what vedolizumab (sold as Entyvio) is, what clinical trials have shown, and what the recently approved at-home injection option means for patients like you.

Key Takeaways

• Vedolizumab (Entyvio) is a gut-selective biologic that blocks the alpha-4-beta-7 integrin, keeping inflammatory cells out of the intestinal lining without broadly suppressing the immune system (1)(6)
• In the GEMINI 2 trial, 39.0% of patients on vedolizumab every 8 weeks achieved clinical remission at week 52 compared with 21.6% on placebo (2)
• The FDA approved subcutaneous Entyvio (the Entyvio Pen, 108 mg every 2 weeks) in April 2024, allowing patients to self-inject at home after initial IV induction (4)
• A 2025 meta-analysis of 73 real-world studies covering nearly 30,000 Crohn's patients found vedolizumab treatment persistence of 65.3% at one year and 54.8% at two years (7)
• Vedolizumab shows a favorable safety profile with no increased risk of serious or opportunistic infections compared to other biologics (8)

What Is Vedolizumab and How Does It Work?

Vedolizumab is a humanized monoclonal antibody that targets the alpha-4-beta-7 integrin on a subset of immune cells called memory T-lymphocytes. By blocking this integrin, vedolizumab prevents these cells from binding to MAdCAM-1 on the blood vessel walls in the gut, which stops them from migrating into inflamed intestinal tissue (1)(6). It was first approved by the FDA in May 2014 for moderately to severely active Crohn's disease and ulcerative colitis in adults (6).

Targeting the Alpha-4-Beta-7 Integrin in the Gut

Think of the alpha-4-beta-7 integrin as a kind of key that inflammatory white blood cells use to enter the intestinal wall. MAdCAM-1, found on blood vessels in the gut lining, acts as the lock. Vedolizumab effectively blocks that key so these cells cannot pass through the lock and reach the gut tissue. The result is reduced inflammation where Crohn's disease is active - in the intestinal lining itself. This mechanism is distinct from older biologics like anti-TNF therapies, which work by neutralizing an inflammatory protein throughout the entire body. As we explored in our overview of biologic treatments past and present, vedolizumab represents a different philosophical approach to managing gut inflammation.

Why "Gut-Selective" Matters for Patients

The term "gut-selective" means that vedolizumab acts primarily in the gastrointestinal tract rather than suppressing the immune system body-wide. Unlike anti-TNF therapies, which reduce TNF-alpha everywhere in the body, vedolizumab's effect is more localized. For patients concerned about infection risk - particularly older adults or those with a history of frequent infections - this selective action can be a meaningful advantage. It is still classified as an immunosuppressive therapy, so monitoring is important, but the systemic immune impact is more limited than with broader-acting biologics.

What the GEMINI 2 Trial Showed

GEMINI 2 was the pivotal Phase 3 trial that led to vedolizumab's FDA approval for Crohn's disease. Published in the New England Journal of Medicine in 2013 by Sandborn and colleagues, the study randomized adults with moderately to severely active Crohn's disease to receive either intravenous vedolizumab 300 mg or placebo at weeks 0 and 2 (2). The results revealed a treatment that is notably stronger in the maintenance phase than in early induction.

Induction Results at Week 6

At week 6, 14.5% of vedolizumab-treated patients were in clinical remission compared with 6.8% on placebo (P=0.02) (2). While this was statistically significant, the CDAI-100 response - a broader measure of symptom improvement - was not significantly different from placebo. For patients, this means vedolizumab may take longer to show its full effect than some other biologics. Your gastroenterologist should prepare you for a slower onset, which can be frustrating but does not mean the drug is not working.

Maintenance Results at Week 52

This is where vedolizumab truly shines. At week 52, clinical remission rates were 39.0% with vedolizumab every 8 weeks and 36.4% every 4 weeks, compared with just 21.6% on placebo (P less than 0.001 and P=0.004 respectively) (2). Serious adverse events occurred in 24.4% of vedolizumab patients versus 15.3% on placebo, with serious infections in 5.5% versus 3.0%, and anti-drug antibodies developing in 4.0% of patients (2). The key takeaway from GEMINI 2 is that vedolizumab's greatest strength lies in keeping patients who respond in sustained remission over time.

The New Subcutaneous Option: VISIBLE 2 and the Entyvio Pen

For patients who do well on vedolizumab, the idea of eliminating regular infusion-center visits is genuinely exciting. The VISIBLE 2 trial tested exactly that - a subcutaneous formulation that could allow maintenance therapy at home.

What VISIBLE 2 Tested

VISIBLE 2 was a Phase 3, randomized, double-blind, placebo-controlled trial published in 2022 in the Journal of Crohn's and Colitis by Vermeire and colleagues (3). After open-label IV induction at weeks 0 and 2, a total of 410 patients who achieved clinical response at week 6 were randomized to either 108 mg subcutaneous vedolizumab every 2 weeks or placebo through week 50. At week 52, 48.0% of patients on subcutaneous vedolizumab were in clinical remission compared with 34.3% on placebo (P=0.008) (3). Perhaps even more striking, corticosteroid-free clinical remission was 45.3% versus 18.2% (3) - a result that matters deeply for patients hoping to get off steroids and stay off.

Injection-site reactions were the only safety finding specific to the subcutaneous formulation, occurring in just 2.9% of patients (3). This is a reassuringly low rate and similar to what is seen with other self-injectable biologics.

Self-Injection at Home with the Entyvio Pen

On April 18, 2024, the FDA approved subcutaneous Entyvio (108 mg every 2 weeks via the Entyvio Pen) for Crohn's disease maintenance after IV induction (4). This means patients who respond to the initial IV infusions can now continue their treatment at home with a simple self-injection pen. The practical difference this makes in daily life - no scheduling infusion appointments, no time off work, no sitting in a chair for hours - can be significant. The important thing to know is that you still need IV induction to start; the at-home pen is for ongoing maintenance only.

How Does Vedolizumab Compare to Anti-TNF Therapy?

One of the most common questions patients ask is whether vedolizumab is "better" than anti-TNF biologics like infliximab or adalimumab. The honest answer is that it depends on your specific situation.

EVOLVE: Biologic-Naive Patients

The EVOLVE real-world study, published in the European Journal of Gastroenterology and Hepatology in 2024 by Mantzaris and colleagues, compared vedolizumab and infliximab in biologic-naive adults with moderate-to-severe Crohn's disease (5). Twelve-month clinical remission rates were 73.1% with vedolizumab versus 55.2% with infliximab, a difference that was not statistically significant (P=0.31), suggesting comparable effectiveness when used as a first-line biologic (5). What did stand out was safety: serious adverse event rates were significantly lower for vedolizumab than infliximab (43.6 versus 200.9 per 1,000 person-years) (5). For patients starting their first biologic, vedolizumab may offer a gentler safety profile while delivering similar remission rates.

Long-Term Persistence in Real-World Studies

A 2025 systematic review and meta-analysis by Armuzzi and colleagues in the United European Gastroenterology Journal pooled data from 73 real-world studies covering 29,894 Crohn's patients (7). Vedolizumab treatment persistence - meaning patients who stayed on the drug - was 65.3% at one year and 54.8% at two years (7). These real-world persistence rates are encouraging because they reflect how the drug performs outside the controlled environment of clinical trials, in everyday patients with varying disease complexity.

The practical takeaway: vedolizumab tends to be preferred when safety, infection risk, or limiting systemic immune exposure is a priority. Anti-TNF therapies may be chosen when faster onset is essential, or when there is significant perianal fistulizing disease or extra-intestinal manifestations like joint inflammation or skin conditions. Newer options like IL-23 inhibitors add further choices to this conversation.

Safety, Side Effects, and Vaccinations

Understanding what side effects to expect - and which rare events to watch for - helps you feel more in control of your treatment.

Common and Serious Side Effects

Across clinical trials and real-world data, vedolizumab shows a favorable infection profile with no signal of increased serious or opportunistic infection risk compared to other biologics. Clostridial infections, sepsis, and tuberculosis were each reported in fewer than 0.6% of patients (8). Common side effects include nasopharyngitis (common cold symptoms), headache, joint pain, nausea, fever, fatigue, cough, bronchitis, and infusion or injection-site reactions. Independent risk factors for serious infection while on biologics include younger age, corticosteroid use, and use of narcotic pain medications (8).

Vaccines and Infection Risk

Because vedolizumab is classified as an immunosuppressive therapy, vaccine planning matters. Live vaccines are generally avoided while on vedolizumab. Non-live vaccines - including most flu shots, COVID-19 vaccines, and pneumococcal vaccines - are recommended and ideally should be updated before starting therapy. If you are considering vedolizumab and have not had a recent vaccine review, this is worth discussing with your gastroenterologist early in the process.

Is Vedolizumab Right for You? Questions to Ask Your Doctor

Choosing between biologics is one of the most important decisions in Crohn's disease management. As we discussed in our article on top-down versus step-up treatment strategies, the timing and sequencing of therapy matters.

Who Might Benefit Most

Patients who may benefit most from vedolizumab include those who have lost response or had side effects with anti-TNF therapies, older adults concerned about infection risk, and people with isolated luminal (intestinal) Crohn's disease without dominant perianal or systemic extra-intestinal involvement. If you fall into one of these categories, vedolizumab is well worth exploring with your care team.

Limitations to consider: vedolizumab's onset can be slower than anti-TNFs, meaning it may take several months before you feel its full effect. Its effect on perianal fistulizing disease and certain extra-intestinal manifestations (like joint or skin involvement) may be more limited than anti-TNF therapy.

Practical Questions for Your Gastroenterologist

Having specific questions ready for your appointment can make a real difference. Consider asking:

• How soon should I expect to feel better, and what milestones should we look for?
• Will we monitor my response by symptom scores, fecal calprotectin, intestinal ultrasound, or colonoscopy?
• What is the plan if I have not responded adequately by week 14 or week 26?
• Do I need to start with IV infusions, and when can I switch to the at-home Entyvio Pen?
• What infusion schedule (every 8 versus every 4 weeks) makes sense for my situation if response is partial?

One important thing to keep in mind: response to vedolizumab usually builds over weeks to months, not days. Staying on schedule with your doses - no missed infusions or injections - is one of the strongest predictors of long-term remission.

Frequently Asked Questions

Is vedolizumab safe for older adults with Crohn's disease?

Vedolizumab is often considered a favorable option for older adults because of its gut-selective mechanism. Real-world data show lower serious adverse event rates compared to anti-TNF biologics (5). Infection monitoring and vaccine updates remain important, but the limited systemic immunosuppression makes it an appealing choice for patients where infection risk is a priority.

How long does it take for vedolizumab to start working?

Vedolizumab typically has a slower onset than some other biologics. In the GEMINI 2 trial, induction remission rates at week 6 were modest (14.5% versus 6.8% on placebo), but the drug's real strength emerged during maintenance, with 39.0% remission at week 52 (2). Most gastroenterologists evaluate response around weeks 14 to 26.

Can I switch from IV vedolizumab to the Entyvio Pen?

Yes. The FDA-approved pathway allows patients who respond to IV induction to transition to subcutaneous Entyvio (108 mg every 2 weeks) for ongoing maintenance (4). The VISIBLE 2 trial specifically validated this IV-to-subcutaneous switch approach, showing 48.0% clinical remission at week 52 (3). Discuss timing with your gastroenterologist.

Does vedolizumab work for perianal Crohn's disease?

Vedolizumab's evidence for perianal fistulizing disease is more limited than for luminal disease. Anti-TNF therapies generally have stronger data for perianal complications. If perianal disease is a major concern, your gastroenterologist may consider other treatment options first or use vedolizumab alongside additional therapies.

What happens if I miss a dose of vedolizumab?

Staying on schedule is one of the strongest predictors of long-term success with vedolizumab. If you miss an IV infusion or subcutaneous injection, contact your gastroenterologist's office as soon as possible to reschedule. Missed doses can affect drug levels and potentially increase the risk of developing anti-drug antibodies, which may reduce effectiveness.

Is vedolizumab covered by insurance in different countries?

Coverage varies significantly by country and healthcare system. In the United States, most major insurance plans cover vedolizumab for approved indications, though prior authorization may be required. Many countries in Europe, Canada, Australia, and parts of Asia also have vedolizumab on their formularies. Takeda, the manufacturer, offers patient support programs in several regions that may help with access and cost.

What should I ask my doctor before starting vedolizumab?

Key questions include: Am I a candidate for the subcutaneous pen after induction? How will we monitor my response (lab work, imaging, endoscopy)? What is the backup plan if I do not respond by a certain timepoint? Should I update my vaccinations before starting? Your doctor should also discuss whether vedolizumab, an anti-TNF, or an IL-23 inhibitor best fits your disease pattern and history.

References

1. Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK. Vedolizumab: an alpha-4-beta-7 integrin antagonist for ulcerative colitis and Crohn's disease. Therapeutic Advances in Chronic Disease, 2015. Read study
2. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, et al. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine 2013;369(8):711-721. Read study
3. Vermeire S, D'Haens G, Sandborn WJ, et al. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. Journal of Crohn's and Colitis 2022;16(1):27-38. Read study
4. Takeda. FDA Approves Subcutaneous Administration of ENTYVIO (vedolizumab) for Maintenance Therapy in Adults with Moderately to Severely Active Crohn's Disease. April 18, 2024. Read article
5. Mantzaris GJ, Bressler B, Adsul S, et al. Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study. European Journal of Gastroenterology and Hepatology 2024;36(3):281-291. Read study
6. Drugs.com. Entyvio (Vedolizumab) - FDA Approval History and Prescribing Reference. 2024. Read article
7. Armuzzi A, et al. Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-alpha in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis. United European Gastroenterology Journal, 2025. Read study
8. Long-Term Safety of Vedolizumab in Patients With Ulcerative Colitis/Crohn's Disease: A Prospective Observational Study. Clinical Gastroenterology and Hepatology, 2025. Read study